Generic-Drug Makers Actavis, Mylan To Report Q4 Soon

By | February 10, 2014

Scalper1 News

Upcoming earnings reports will reveal if leading generic-drug makers continue to stay healthy. The group ranked No. 11 among the 197 industries tracked by IBD in Monday’s issue, up from No. 23 three months ago. Leaderboard stock Actavis (ACT) boasts a 98 Earnings Per Share Rating and a 99 Composite Rating. The Parsippany, N.J.-based company, which changed its name last year from Watson Pharmaceuticals after acquiring Actavis, reports Scalper1 News

Scalper1 News